---
schema_version: "secwatch.filing_event.v1"
accession: "0001544784-24-000068"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:37:48.427674+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bio-Path Q1 net loss $3.2M ($4.88/sh); raises $3.5M post-quarter

## Summary
- Net loss $3.2M ($4.88 EPS) vs $5.3M ($13.25 EPS) in Q1 2023; R&D expense down to $2.3M from $4.0M.
- Cash at Mar 31 only $0.2M; raised $3.5M in April via $1.2M direct offering and $2.3M ATM sales.
- Completed second dose cohort (40 mg/m2) of Phase 1/1b BP1002 trial for relapsed AML; pause for FDA review.
- Patent portfolio expanded to 5 U.S. and 54 foreign patents covering 21 countries; new applications filed.
- First dose cohort of Phase 1 BP1002 trial for relapsed lymphoma/CLL completed in January.

## SEC filing metadata
- accession: 0001544784-24-000068
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000154478424000068/0001544784-24-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000154478424000068/bpth-20240515x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001544784-24-000068
- JSON: https://secwatch.observer/filing/0001544784-24-000068.json
- Plain text: https://secwatch.observer/filing/0001544784-24-000068.txt

## Key facts
- Earnings Releases
  BIO-PATH HOLDINGS, INC. reported first quarter ended March 31, 2024 results: net income $3.2 million, or $4.88 per share, EPS $4.88 per share.
  - Period: first quarter ended March 31, 2024
  - Net income: $3.2 million, or $4.88 per share
  - EPS: $4.88 per share
  - Result: reported results
  source text: The Company reported a net loss of $3.2 million, or $4.88 per share, for the three months ended March 31, 2024, compared to a net loss of $5.3 million, or $13.25 per share, for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133818/000154478424000068/0001544784-24-000068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.